<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03420040</url>
  </required_header>
  <id_info>
    <org_study_id>KY20172077-1</org_study_id>
    <nct_id>NCT03420040</nct_id>
  </id_info>
  <brief_title>A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use</brief_title>
  <official_title>A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study of the use of glargine insulin in 2 subjects with type two diabetes in China
      was carried out. The two kinds of injection methods were evaluated as subcutaneous injection
      of insulin glargine.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fasting blood glucose between baseline to week 4</measure>
    <time_frame>baseline and week 4</time_frame>
    <description>fasting blood glucose are measured at baseline and week 4</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>QS-M Needle Free Injector group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To observe the use of insulin in glycemia under good blood glucose control in the QS-M Needle Free Injector group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glargine pen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To observe the amount of insulin used by the Glargine pen group under good blood glucose control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QS-M Needle Free Injector</intervention_name>
    <description>The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection</description>
    <arm_group_label>QS-M Needle Free Injector group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glargine pen</intervention_name>
    <description>The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection</description>
    <arm_group_label>Glargine pen group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male or female aged 18-70 years of age, women of childbearing age need to take
             adequate contraceptive measures to minimize the risk of pregnancy;

          2. the standard of diagnosis of type 2 diabetes and the course of the disease is more
             than half a year;

          3. 18 Kg/m2 = BMI = 30Kg/m2;

          4. received daily injections of insulin glargine and also take one to three kinds of oral
             medicine (not including secretagogues) patients, daily insulin glargine total dose
             more than 12IU but &lt;50IU, the use of insulin glargine than in January;

          5. the blood glucose in the fasting vein was in 5.0-9.0mmol/L;

          6. the letter of informed consent has been read and signed.

        Exclusion Criteria:

          1. there is conflict of interest with this research.

          2. blood glucose control is not good enough to participate in this study, such as
             repeated hypoglycemia, diabetic ketoacidosis or hyperosmolar coma.

          3. serious diabetic complications such as diabetic foot, diabetic nephropathy and so on;

          4. severe cardiovascular events occurred in the last 6 months.

          5. the application of hormone or immunosuppressant, or low immunity defect;

          6. the use of non steroidal anti-inflammatory drugs;

          7. the use of sulfonylureas and insulin secreting agents;

          8. a person with a history of cancer;

          9. a history of unstable or rapid progressive renal disease;

         10. an unstable history of major mental illness;

         11. the history of hemoglobin (such as sickle red cell anemia, thalassemia, iron
             granulocytic anemia);

         12. women who are pregnant or are breastfeeding;

         13. in the near future there is a clear infection, such as urinary tract infection and
             pneumonia;

         14. recent important visceral hemorrhage, such as gastric hemorrhage and cerebral
             hemorrhage, etc.

         15. skin diseases such as exfoliative dermatitis, pustular sore and infection of pyogenic
             bacteria;

         16. the history of acute pancreatitis or pancreatectomy;

         17. the researchers believe that it may lead to any situation in which the subject is
             unable to complete the study or may cause significant risk to the subject.

         18. the results of the laboratory examination are as follows: A. obvious abnormal liver
             function or in the active phase of the disease (AST&gt; 3 times the upper limit of normal
             ALT&gt; or 3 times the upper limit of normal); The creatinine clearance rate of B. was
             &lt;60ml/min; C. anaemia caused by any cause of the disease; The results of pregnancy
             test in women of childbearing age of D. were positive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiuhe Ph.D Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, Xijing Hospital, Fourth Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical university</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glargine Insulin</keyword>
  <keyword>QS-M Needle Free Injector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

